The present invention relates to a reactor for the bulk manufacture of PCR amplicons, as well as methods of amplifying PCR amplicons.
DNA vaccines have proven effective in a growing number of infectious disease indications. For example, influenza is a highly contagious illness of the respiratory tract caused by RNA viruses of the Orthomyxoviridae family (Knipe & Howley). According to the Centers for Disease Control and Prevention, five to 20% of the U.S. population gets influenza every year, with about 36,000 deaths annually due to complications from the infection. Influenza is among the top seven leading causes of death in the U.S. despite over 60 years of licensed influenza vaccine availability; still, the most effective protection against influenza infection is vaccination. Small periodic changes in the virus surface antigens (antigenic drift) require the development of new vaccines every season. Moreover, major changes in the virus surface proteins (antigenic shift) can result in highly virulent strains that have the potential to cause a pandemic. Outbreaks of influenza in animals increase the chances of a pandemic, through the reshuffling of animal and human influenza virus genomes resulting in a new virus strain. A recent pandemic outbreak of a new strain of an influenza A virus subtype H1N1, officially referred to as the novel H1N1, first identified in April 2009 has raised new concerns of current vaccination strategies. It has become clear that successful containment of an outbreak of a highly virulent influenza strain will require fast manufacture of large quantities of vaccines.
While vaccination against influenza has been reported as the most cost-effective approach, development and manufacture of influenza vaccines require the use of technologies that have proven slow and unreliable and are therefore inadequate to meet the challenges of a potentially rapidly changing and spreading pandemic. One potential technology that may meet the requirements for rapid manufacture of vaccines is plasmid DNA (pDNA). However, pharmaceutical grade pDNA production requires bacterial fermentation followed by lengthy purification and extensive quality control testing. There are also some concerns that trace amounts of antibiotics and other fermentation components may carry over after purification. Ideally, a nucleic acid vaccine could be produced using a cell-free system more akin to a small molecule synthetic process.
There is a need for an amplicon reactor to automate the amplification process and quickly amplify an amplicon such as but not limited to a piece of linear RNA or alternatively DNA that may or may not encode a gene product.
The present invention is directed to a reactor used for amplification of a piece of DNA or RNA, also generally referred to herein as an amplicon. Two types of reactors are disclosed, a batch amplicon reactor in which the amplicon being part of a PCR mixture is heated and cooled in a reaction chamber, and a continuous flow reactor in which the amplicon being part of a PCR mixture is heated and cooled as it flows through heat exchanger modules having different temperatures.
In one embodiment, a reactor is disclosed for the production of a linear expression cassette (LEC), that is, a linear piece of DNA that is capable of expressing a gene product, from a polymerase chain reaction (PCR) mix. The reactor includes a housing having at least one reaction chamber therein surrounded by a fluid path for heat transfer. The heat transfer fluid necessary for heat transfer enters the housing through a fluid inlet and exists by way of a fluid outlet. The reaction chambers, storing the PCR reaction mixture, are positioned within the housing in thermal communication with the heat transfer fluid (HT fluid) flowing in the fluid path to heat and/or cool the reaction chambers. A variable temperature HT fluid source is in fluid communication with the fluid inlet and the HT fluid source is configured to provide HT fluid at temperatures suitable for amplification, including a denature temperature, an anneal temperature, and/or an extension temperature. A controller is coupled to the variable temperature HT fluid source to control a HT fluid temperature within the fluid path by controlling the variable temperature HT fluid source.
In some embodiments, the variable temperature HT fluid source is a plurality of HT fluid baths at different temperatures with outlet valves in fluid communication with the fluid inlet of the housing. The controller opens and closes the outlet valves of the HT fluid baths to control the fluid temperature within the housing.
In some embodiments, the variable temperature HT fluid source is a steam source and a liquid source coupled to a steam/water mixing valve in fluid communication with the fluid inlet. The controller adjusts the steam/water mixing valve to control the HT fluid temperature within the housing.
In another embodiment, a method of amplification of an amplicon to produce a linear expression cassette (LEC) is disclosed using a batch reactor. The method includes providing a reactor having a housing, one or more reaction chambers positioned within the housing in thermal communication with the HT fluid flowing in a fluid path to heat and/or cool the reaction chambers, a variable temperature HT fluid source to provide HT fluid at temperatures suitable for amplification, including a denature temperature, an anneal temperature, and/or an extension temperature, and a controller coupled to the variable temperature HT fluid source to control the HT fluid temperature within the fluid path by controlling the variable temperature HT fluid source. The PCR reaction mixture including the amplicon is placed within the one or more reaction chambers and then heated and cooled within the reaction chambers for an amplification process cycle by flowing HT fluid in the fluid path at a plurality of temperatures and time periods in order to produce a linear expression cassette.
In another embodiment, a continuous flow reactor is disclosed for amplification of an amplicon. The reactor includes a plurality of heat exchanger modules constructed of plate heat exchangers, with each heat exchanger module having an amplicon fluid path combinable into a continuous amplicon fluid path passing through the plurality of heat exchanger modules. A plurality of HT fluid sources provide heating/cooling fluids to a heating/cooling fluid path of each heat exchanger module at temperatures suitable for amplification, including a denature temperature, an anneal temperature, and/or an extension temperature. A controller coupled to the plurality of HT fluid sources is configured to control a temperature within each of the plurality of heat exchanger modules by controlling an HT fluid temperature and/or fluid flow rate through the heating/cooling fluid path.
The present invention is directed to a reactor for the bulk manufacture of PCR amplicons. The amplicon to be amplified may be a linear piece of DNA or RNA and may be capable of expressing a polypeptide. The amplicon is heated and cooled for amplification. An amplification cycle of the amplicon may include the following: a denature step, an annealing step, and an extension step. The PCR reaction carried out according to the present invention is thus capable of producing bulk quantities of the desired amplicon or template. Thus, depending on the amplicon it is possible to generate commercial quantities of that particular amplicon. Large quantities of an amplicon would be useful in a wide variety of applications, such as but not limited to, linear expression cassettes that may be useful as vaccines; oligonucleotides that may be useful as adjuvants by themselves or with vaccines, inhibitory or stimulatory DNA pharmaceuticals, and linear expression cassette transfections.
Two types of reactors are disclosed herein: a batch reactor and a continuous flow reactor. At the heart of the batch reactor disclosed in the present invention there exists a heat exchanger of which there can be many variations on the shell and tube design. A shell and tube heat exchanger is a class of heat exchanger designs and as its name implies, this type of heat exchanger consists of a shell (a large pressure vessel) with a bundle of tubes inside it. One fluid runs through the tubes, and another fluid flows over the tubes (through the shell) to transfer heat between the two fluids. The set of tubes is called a tube bundle, and may be composed by several types of tubes: plain, longitudinally finned, etc. There can be many variations on the shell and tube design. Typically, the ends of each tube are connected to plenums (sometimes called water boxes) through holes in tube sheets. The tubes may be straight or bent in the shape of a U, called U-tubes. Most shell-and-tube heat exchangers are either 1, 2, or 4 pass designs on the tube side. This refers to the number of times the fluid in the tubes passes through the fluid in the shell. In a single pass heat exchanger, the fluid goes in one end of each tube and out the other.
Alternatively, the tubes may be closed at both ends thereby forming a plurality of individual reaction chambers. In this particular embodiment the PCR mixture containing the desired amplicon is placed within reaction chambers and a thermal heat transfer fluid (HT fluid) flows around the chambers, heating and cooling the amplicon for amplification. In the continuous flow reactor, the PCR mixture containing the desired amplicon flows through heat exchanger modules at different temperatures, heating and/or cooling the amplicon for amplification.
Taking into account the thermal design features discussed above reactor housing 102 and reaction chambers 110 may be any suitable size and shape and be made of any material having a high ratio of thermal conductivity. Typically, the tubes which make up reaction chambers 110 are double or single tube sheet, cylindrical in shape and when bundled together and positioned within reaction chamber 110 are best shown in
In some embodiments, reaction chambers 110 are positioned in a vertical configuration and the amplicon is loaded from a bottom end toward a top end.
Reactor 100 further includes a variable temperature HT fluid source connected to fluid inlet 104.
Fluid baths 114, 116, 118 are connected to fluid inlet 104 via a first common fluid line 120 and connected to fluid outlet 106 via a second common fluid line 122. First fluid line 120 may also include a booster pump 124 to pump the fluid between 1 and 100 liters/min. through the HT fluid path 108. First fluid bath 114 includes a first outlet valve 126 coupled to inlet 104 via first common fluid line 120 and a first fluid inlet valve 128 coupled to outlet 106 via second common fluid line 122. Second fluid bath 116 includes a second outlet valve 130 coupled to inlet 104 and a second fluid inlet 132 coupled to outlet 106 via second common fluid line 122. Third fluid bath 118 includes a third fluid outlet 134 coupled to inlet 104 first common fluid line 120 and a third fluid inlet 136 coupled to outlet 106 via second common fluid line 122. A controller 138 is connected to fluid outlet valves 126, 130, 134 and fluid inlet valves 128, 132, 136 and controls their opening and closing. By opening and closing fluid outlet valves 126, 130, 134 and fluid inlet valves 128, 132, 136, controller 138 is able to control the fluid temperature in fluid path 108 within reactor housing 102. Controller 138 is capable of controlling temperature ramp rates between 1° C./sec and 10° C./sec. Various thermocouples or other temperature measuring sensors 140 are coupled to the controller 138 to monitor fluid temperatures flowing through reactor 100.
For amplicon amplification, the amplicon is positioned within reaction chambers 110 and sealed. Reaction chambers 110 are positioned within housing 102. First outlet valve 126 and first fluid inlet valve 128 are opened by controller 138 and a HT first fluid 142 from first fluid bath 114 flows through HT fluid path 108 contacting reaction chambers 110. First fluid 142 may be at a denature temperature between 90-99° C. and flows for 5-60 seconds, denaturing the amplicon within chambers 110. After denaturing is complete, controller 138 closes first outlet valve 126 and first fluid inlet valve 128. Controller 138 then opens second outlet valve 130 and second fluid inlet 132 of second fluid bath 116 and a second HT fluid 144 flows through HT fluid path 108 contacting reaction chambers 110. Second HT fluid 144 may be at an anneal temperature between 45-72° C. and flows for 5-45 seconds, annealing the amplicon within chambers 110. After annealing is complete, controller 138 closes second outlet valve 130 and second fluid inlet 132. Controller 138 then opens third outlet valve 134 and third fluid inlet 136 of third fluid bath 118 and a third HT fluid 146 flows through HT fluid path 108 contacting reaction chambers 110. Third HT fluid 146 may be at an extension temperature between 65-75° C. and flows for 90-300 seconds, extending the amplicon within chambers 110. After extension is complete, controller 138 closes third outlet valve 134 and third fluid inlet 136. One amplification cycle of the LEC material within chambers 110 is now complete. If desired, more cycles may be done by repeating the previous steps. In addition, one or more steps may be done separately or repeated. For example, an initial step may be done of flowing the first fluid at a denature temperature for an initial denature step. Another example is a final step may be done of flowing the third HT fluid at an extension temperature for a final extension step. In some embodiments the amplicon may be removed from chambers 110. In other embodiments, the amplicon may remain in chambers 110 and cooled to about 4° C. Once the amplicon has been removed, chambers 110 may be chemically cleaned. While one example of an amplification process cycle has been disclosed above, other process cycles are contemplated using other HT fluid temperatures and times.
Reactor 200 includes a reactor housing 202 having a fluid inlet 204 and a fluid outlet 206 with an HT fluid path 208 there between. A number of reaction chambers 210 are positioned within HT fluid path 208 of housing 202 such that the HT fluid flows around reaction chambers 210. End caps 212 and 212′ may be used to seal ends of housing 202. In some embodiments, end caps 212 and 212′ may also be used to seal reaction chambers 210, if the chambers are not already sealed with the amplicon inside.
Reactor 200 further includes a variable temperature HT fluid source connected to fluid inlet 204.
A controller 238 is connected to steam/water mixing valve 250 and controls the opening and closing of an internal valve. By opening and closing the internal valve, controller 238 is able to control the fluid temperature in HT fluid path 208 within reactor housing 202. Controller 238 is capable of controlling temperature ramp rates between 1° C./sec and 10° C./sec. Various thermocouples or other temperature measuring sensors 240 are coupled to the controller 238 to monitor HT fluid temperatures flowing through the reactor 200.
For amplicon amplification, the amplicon is positioned within reaction chambers 210 and sealed. Reaction chambers 210 are positioned within housing 202. Controller 238 controls the valve position of the internal valve in steam/water mixing valve 250 to deliver fluids at suitable temperatures to inlet 204 and HT fluid path 208 for amplification of the amplicon. In a first valve position, steam/water mixing valve 250 delivers a first HT fluid at a denature temperature between 90-99° C. and flows for 5-60 seconds through fluid path 208 contacting reaction chambers 210, denaturing the amplicon within chambers 210. In a second valve position, steam/water mixing valve 250 delivers a second HT fluid at an anneal temperature between 45-72° C. and flows for 15-45 seconds through fluid path 208 contacting reaction chambers 210, annealing the amplicon within chambers 210. In a third valve position, steam/water mixing valve 250 delivers a third HT fluid at an extension temperature between 65-75° C. and flows for 90-300 seconds through fluid path 208 contacting reaction chambers 210, extending the amplicon within chambers 210. The amplification of the amplicon within chambers 210 is now complete. In some embodiments the amplicon may be removed from chambers 210. In other embodiments, the amplicon may remain in chambers 210 and be cooled to about 4° C. Once the amplicon has been removed, chambers 210 may be chemically cleaned. While one example of an amplification process cycle has been disclosed above, other process cycles are contemplated using other fluid temperatures and times.
The heat exchangers discussed above and shown in
As shown in
The inner diameter of the tubing will affect the positioning of the tubes as they are sandwiched between plates 516. Larger diameter tubes will be configured as shown in
FIGS. 9A,94B and 9C show one embodiment of a continuous flow reactor 400 used for amplification of a LEC material passing through heat exchanger modules at different temperatures, heating and cooling the amplicon for amplification. Reactor 900 includes first, second and third heat exchanger modules 902, 912, 922. First heat exchanger module 902 is constructed of a first plate heat exchanger having a PCR reaction mixture containing the amplicon fluid path 904 passing through the first heat exchanger module 902 from a first fluid inlet 906 to a first fluid outlet 908. Second heat exchanger module 912 is constructed of a second plate heat exchanger having an amplicon fluid path 914 passing through second heat exchanger module 912 from a second fluid inlet 916 to a second fluid outlet 918. Third heat exchanger module 922 is constructed of a third plate heat exchanger having an amplicon fluid path 924 passing through third heat exchanger module 922 from a third fluid inlet 926 to a third fluid outlet 928. The plate heat exchangers may be either electrically heated/cooled or may use a fluid passing through the plate heat exchanger for heating or cooling. Suitable plate heat exchangers may be purchased from sources including ITT Standard, Cheektowaga, N.Y.; Mueller, Springfield, Mo.; Alfa Laval Corporation AB, Sweden; GEA PHE Systems York, Pa.; and APV Getzville, N.Y.
In the embodiment shown in
Various valves are opened and closed to direct the PCR reaction mixture containing the amplicon to the fluid paths 904, 914, 924 of the different heat exchanger modules 902, 912, 922, depending on the amplification cycle. A controller 930 may be coupled to various valves and to control the opening and closing of the valve. Controller 930 may also control one or more pumps in the reactor.
One embodiment of an amplification cycle is shown in
For amplicon amplification, PCR reaction mixture containing the amplicon is introduced into Loop A through a valve 932 then closed. Valves 934, 936 are opened and the PCR reaction mixture containing the amplicon is pumped around Loop A through fluid path 904 of first heat exchanger module 902 using a pump 938 for an initial denature step at a denature temperature between 90-99° C., as shown in
In use, the PCR reaction mixture containing the amplicon is loaded in an inlet 1032 and goes through heat exchanger module 1002 for an initial denature 1008. The PCR reaction mixture containing the amplicon then goes through multiple cycles 1010 by going through multiple sets of first, second and third heat exchanger modules 1004, 1012 and 1022 arranged in series. After a final extension step 1011 through third heat exchanger modules 1024, the amplified amplicon is harvested as it exits through the outlet 1052. Pump 1038 pumps the material through the continuous fluid path. The number of cycles 1010 is determined by the amplification and may be between 2 and 100.
While the exemplary embodiments have been described in some detail, by way of example and for clarity of understanding, those of skill in the art will recognize that a variety of modification, adaptations, and changes may be employed. Hence, the scope of the present invention should be limited solely by the appending claims.
This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application No. 61/247,887, filed Oct. 1, 2009, which is related to U.S. patent application Ser. No. 11/949,745, entitled “Linear Expression Cassette Vaccines”, filed Dec. 3, 2007, both of which are fully incorporated herein by reference.
Some work described herein was partially funded by DARPA grant W911NF-05-1-0545. The U.S. Federal Government has certain rights in the disclosed invention.
Number | Date | Country | |
---|---|---|---|
61247887 | Oct 2009 | US |